Continued use of trastuzumab following disease progression in metastatic breast cancer.pub
ثبت نشده
چکیده
• Trastuzumab (HerceptinTM) is a recombinant humanised monoclonal antibody that inhibits the proliferation of human tumour cells that overexpress the human epidermal growth factor receptor 2 (HER2). In patients with metastatic breast cancer whose tumours overexpress HER2, trastuzumab is licensed as monotherapy or combination therapy with other chemotherapy or hormonal agents until progression of disease. It is not licensed for use following disease progression.
منابع مشابه
Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment.
Central nervous system (CNS) metastases from breast cancer are common and can present as the first or solitary site of disease progression. The CNS has been reported to act as a sanctuary site that denies access to many chemotherapeutic agents. We present here, a series of 10 metastatic breast cancer patients who developed CNS metastases after an initial response to trastuzumab treatment. Forty...
متن کاملEfficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
BACKGROUND The Hermine study observed the use of trastuzumab for metastatic breast cancer (MBC) in routine practice, including patients who received trastuzumab treatment beyond progression (TBP). PATIENTS AND METHODS The study observed 623 patients for > or = 2 years. Treatment was given according to oncologists' normal clinical practices. Endpoints included duration of treatment, efficacy, ...
متن کاملGemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Gemcitabine (Gemzar) and paclitaxel show good activity as single agents and combined in metastatic breast cancer, and the combination of paclitaxel/trastuzumab (Herceptin) has been shown to prolong time to disease progression and survival significantly in this setting. Preclinical data indicate additive or synergistic effects of gemcitabine and trastuzumab in HER2-positive human breast cancer c...
متن کاملPertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Overexpression of HER2 - found in approximately 15-20% of all breast cancers - is a negative prognostic factor. Although trastuzumab significantly improves the prognosis of HER2-positive breast cancer, half of the patients with metastatic breast cancer experience disease progression within 1 year. Pertuzumab is a novel HER2-targeted humanized monoclonal antibody that binds to the dimerization d...
متن کاملCurrent and future anti-HER2 therapy in breast cancer.
The therapeutic strategy for breast cancer with the use of targeted drugs is, at present, mainly focused on coping with HER2. Currently, lapatinib and trastuzumab are in widespread use. Virtually all completed and in progress clinical trials have demonstrated a significant enhancement in the rate of pathologic complete response (pCR), the primary endpoint in these studies, in cases of patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2010